Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 7:36 PM
Ignite Modification Date:
2025-12-25 @ 5:17 PM
NCT ID:
NCT00919503
Group ID:
EG000
Title:
Regimen A (PBSCT and BMT)
Description:
CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
Allogeneic Bone Marrow Transplantation: Infused IV
Anti-Thymocyte Globulin: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Methotrexate: Given IV
Peripheral Blood Stem Cell Transplantation: Infused IV
Tacrolimus: Given IV or PO
Treosulfan: Given IV
Deaths Number Affected:
7
Deaths Number At Risk:
None
Serious Number Affected:
17
Serious Number At Risk:
84
Other Number Affected:
53
Other Number At Risk:
84
Study:
NCT00919503
Results Section:
NCT00919503
Adverse Events Module:
NCT00919503